Garcia-Montoya Leticia, Marzo-Ortega Helena
NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
LIRMM, University of Leeds, Second floor, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK.
Ther Adv Musculoskelet Dis. 2018 Sep 6;10(9):169-180. doi: 10.1177/1759720X18787766. eCollection 2018 Sep.
Psoriatic arthritis and ankylosing spondylitis are chronic inflammatory diseases that can cause significant disability. The commercialization of the first tumour necrosis factor (TNF) inhibitors led to a radical improvement of the quality of life of people affected by these conditions; however, response was not universal, highlighting the need for alternative therapeutic targets. Secukinumab is a monoclonal interleukin (IL)-17A inhibitor which has been proven efficacious for psoriatic arthritis and ankylosing spondylitis in recent clinical trials. Dactylitis, enthesitis, skin and nails are some of the domains in which the inhibition of IL-17 has shown significant improvements apart from the joints. Its safety profile and satisfactory medium- to long-term outcome data are some of the aspects suggesting its potential impact in treatment protocols in the short term.
银屑病关节炎和强直性脊柱炎是可导致严重残疾的慢性炎症性疾病。首批肿瘤坏死因子（TNF）抑制剂的商业化使这些疾病患者的生活质量得到了根本性改善；然而，并非所有患者都有反应，这凸显了寻找替代治疗靶点的必要性。司库奇尤单抗是一种单克隆白细胞介素（IL）-17A抑制剂，在最近的临床试验中已被证明对银屑病关节炎和强直性脊柱炎有效。除关节外，指（趾）炎、附着点炎、皮肤和指甲等部位的IL-17抑制也显示出显著改善。其安全性和令人满意的中长期疗效数据表明，它在短期内可能会对治疗方案产生影响。
